CDCs can be functionalized to target a wide range of solid and liquid tumors
Elucida is pursuing two lead CDC programs with plans for follow-on programs upon proof of concept:
- A folate receptor targeted topoisomerase 1 inhibitor CDC for the treatment of platinum resistant ovarian cancer
- A non-targeted EGFR tyrosine kinase inhibitor CDC for the treatment of brain cancers (primary gliomas and other cancers that have metastasized to the brain) that takes advantage of the intrinsic ability of CDCs to cross disrupted blood brain barrier and localize in brain tumors
Folate Receptor Targeted CDCs:
The folate receptor is a validated target for ovarian cancer as demonstrated in numerous clinical trials. Elucida is testing highly potent folate receptor targeted topoisomerase 1 inhibitor payloads to create the next generation targeted therapeutics for ovarian cancer. Elucida’s CDCs have the potential to be thousands of times more potent than current therapies without the off-target effects and toxicity that limit existing treatments.
Because CDCs can be functionalized to target a wide range of tumors, upon proof of concept, Elucida plans to expand the indications that we are targeting with our lead compound:
EGFR Tyrosine Kinase Inhibitor CDCs:
The blood-brain barrier (BBB) is exceptionally good at keeping out most cancer drugs and is the main reason why cancer treatments that work elsewhere routinely fail when directed at the brain. Current treatments for primary and secondary brain tumors - surgery, radiation and chemotherapy – are inadequate, resulting in survival typically measured in months.
The BBB actively pumps molecules and drugs in or out of the brain. Traversing the barrier is difficult for large, lipid-insoluble biological drugs like antibody-drug conjugates (ADCs). Molecules that efficiently cross the BBB tend to be small and have a high solubility in lipids. Molecularly targeted kinase inhibitors (e.g. gefitinib) can be particularly affected.
Elucida’s CDCs have the ability to efficiently penetrate through disrupted BBB while carrying/delivering drugs that are not able to efficiently cross on their own